Azurin interaction with the lipid raft components ganglioside GM-1 and caveolin-1 increases membrane fluidity and sensitivity to anti-cancer drugs

Nuno Bernardes, Ana Rita Garizo, Sandra N. Pinto, Bernardo Caniço, Catarina Perdigão, Fábio Fernandes, Arsénio M. Fialho

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Membrane lipid rafts are highly ordered microdomains and essential components of plasma membranes. In this work, we demonstrate that azurin uptake by cancer cells is, in part, mediated by caveolin-1 and GM-1, lipid rafts’ markers. This recognition is mediated by a surface exposed hydrophobic core displayed by azurin since the substitution of a phenylalanine residue in position 114 facing the hydrophobic cavity by alanine impacts such interactions, debilitating the uptake of azurin by cancer cells. Treating of cancer cells with azurin leads to a sequence of events: alters the lipid raft exposure at plasma membranes, causes a decrease in the plasma membrane order as examined by Laurdan two-photon imaging and leads to a decrease in the levels of caveolin-1. Caveolae, a subset of lipid rafts characterized by the presence of caveolin-1, are gaining increasing recognition as mediators in tumor progression and resistance to standard therapies. We show that azurin inhibits growth of cancer cells expressing caveolin-1, and this inhibition is only partially observed with mutant azurin. Finally, the simultaneous administration of azurin with anticancer therapeutic drugs (paclitaxel and doxorubicin) results in an enhancement in their activity, contrary to the mutated protein.

Original languageEnglish
Pages (from-to)1649-1666
Number of pages18
JournalCell Cycle
Volume17
Issue number13
DOIs
Publication statusPublished - 3 Jul 2018

Fingerprint

Azurin
Caveolin 1
Membrane Fluidity
Gangliosides
Lipids
Pharmaceutical Preparations
Neoplasms
Cell Membrane
Caveolae
Membrane Lipids
Paclitaxel
Phenylalanine
Photons
Alanine
Doxorubicin

Keywords

  • Azurin
  • caveolin-1
  • lipid raft
  • membrane order
  • membrane-based anticancer therapy

Cite this

Bernardes, Nuno ; Garizo, Ana Rita ; Pinto, Sandra N. ; Caniço, Bernardo ; Perdigão, Catarina ; Fernandes, Fábio ; Fialho, Arsénio M. / Azurin interaction with the lipid raft components ganglioside GM-1 and caveolin-1 increases membrane fluidity and sensitivity to anti-cancer drugs. In: Cell Cycle. 2018 ; Vol. 17, No. 13. pp. 1649-1666.
@article{0872913442a442babf45699a0bec90a7,
title = "Azurin interaction with the lipid raft components ganglioside GM-1 and caveolin-1 increases membrane fluidity and sensitivity to anti-cancer drugs",
abstract = "Membrane lipid rafts are highly ordered microdomains and essential components of plasma membranes. In this work, we demonstrate that azurin uptake by cancer cells is, in part, mediated by caveolin-1 and GM-1, lipid rafts’ markers. This recognition is mediated by a surface exposed hydrophobic core displayed by azurin since the substitution of a phenylalanine residue in position 114 facing the hydrophobic cavity by alanine impacts such interactions, debilitating the uptake of azurin by cancer cells. Treating of cancer cells with azurin leads to a sequence of events: alters the lipid raft exposure at plasma membranes, causes a decrease in the plasma membrane order as examined by Laurdan two-photon imaging and leads to a decrease in the levels of caveolin-1. Caveolae, a subset of lipid rafts characterized by the presence of caveolin-1, are gaining increasing recognition as mediators in tumor progression and resistance to standard therapies. We show that azurin inhibits growth of cancer cells expressing caveolin-1, and this inhibition is only partially observed with mutant azurin. Finally, the simultaneous administration of azurin with anticancer therapeutic drugs (paclitaxel and doxorubicin) results in an enhancement in their activity, contrary to the mutated protein.",
keywords = "Azurin, caveolin-1, lipid raft, membrane order, membrane-based anticancer therapy",
author = "Nuno Bernardes and Garizo, {Ana Rita} and Pinto, {Sandra N.} and Bernardo Cani{\cc}o and Catarina Perdig{\~a}o and F{\'a}bio Fernandes and Fialho, {Ars{\'e}nio M.}",
note = "info:eu-repo/grantAgreement/FCT/5876/147338/PT# info:eu-repo/grantAgreement/FCT/SFRH/SFRH{\%}2FBPD{\%}2F98162{\%}2F2013/PT# PTDC/EBBBIO/100326/2008; FAPESP/20107/2014; PPBI-POCI-01-0145-FEDER-022122; Programa Operacional Regional de Lisboa 2020 (Project N. 007317); SFRH/BD/122636/2016 to ARG; SFRH/BPD/92409/2013 to SNP; IF/00386/2015 to FF.",
year = "2018",
month = "7",
day = "3",
doi = "10.1080/15384101.2018.1489178",
language = "English",
volume = "17",
pages = "1649--1666",
journal = "Cell Cycle",
issn = "1538-4101",
publisher = "Landes Bioscience",
number = "13",

}

Azurin interaction with the lipid raft components ganglioside GM-1 and caveolin-1 increases membrane fluidity and sensitivity to anti-cancer drugs. / Bernardes, Nuno; Garizo, Ana Rita; Pinto, Sandra N.; Caniço, Bernardo; Perdigão, Catarina; Fernandes, Fábio; Fialho, Arsénio M.

In: Cell Cycle, Vol. 17, No. 13, 03.07.2018, p. 1649-1666.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Azurin interaction with the lipid raft components ganglioside GM-1 and caveolin-1 increases membrane fluidity and sensitivity to anti-cancer drugs

AU - Bernardes, Nuno

AU - Garizo, Ana Rita

AU - Pinto, Sandra N.

AU - Caniço, Bernardo

AU - Perdigão, Catarina

AU - Fernandes, Fábio

AU - Fialho, Arsénio M.

N1 - info:eu-repo/grantAgreement/FCT/5876/147338/PT# info:eu-repo/grantAgreement/FCT/SFRH/SFRH%2FBPD%2F98162%2F2013/PT# PTDC/EBBBIO/100326/2008; FAPESP/20107/2014; PPBI-POCI-01-0145-FEDER-022122; Programa Operacional Regional de Lisboa 2020 (Project N. 007317); SFRH/BD/122636/2016 to ARG; SFRH/BPD/92409/2013 to SNP; IF/00386/2015 to FF.

PY - 2018/7/3

Y1 - 2018/7/3

N2 - Membrane lipid rafts are highly ordered microdomains and essential components of plasma membranes. In this work, we demonstrate that azurin uptake by cancer cells is, in part, mediated by caveolin-1 and GM-1, lipid rafts’ markers. This recognition is mediated by a surface exposed hydrophobic core displayed by azurin since the substitution of a phenylalanine residue in position 114 facing the hydrophobic cavity by alanine impacts such interactions, debilitating the uptake of azurin by cancer cells. Treating of cancer cells with azurin leads to a sequence of events: alters the lipid raft exposure at plasma membranes, causes a decrease in the plasma membrane order as examined by Laurdan two-photon imaging and leads to a decrease in the levels of caveolin-1. Caveolae, a subset of lipid rafts characterized by the presence of caveolin-1, are gaining increasing recognition as mediators in tumor progression and resistance to standard therapies. We show that azurin inhibits growth of cancer cells expressing caveolin-1, and this inhibition is only partially observed with mutant azurin. Finally, the simultaneous administration of azurin with anticancer therapeutic drugs (paclitaxel and doxorubicin) results in an enhancement in their activity, contrary to the mutated protein.

AB - Membrane lipid rafts are highly ordered microdomains and essential components of plasma membranes. In this work, we demonstrate that azurin uptake by cancer cells is, in part, mediated by caveolin-1 and GM-1, lipid rafts’ markers. This recognition is mediated by a surface exposed hydrophobic core displayed by azurin since the substitution of a phenylalanine residue in position 114 facing the hydrophobic cavity by alanine impacts such interactions, debilitating the uptake of azurin by cancer cells. Treating of cancer cells with azurin leads to a sequence of events: alters the lipid raft exposure at plasma membranes, causes a decrease in the plasma membrane order as examined by Laurdan two-photon imaging and leads to a decrease in the levels of caveolin-1. Caveolae, a subset of lipid rafts characterized by the presence of caveolin-1, are gaining increasing recognition as mediators in tumor progression and resistance to standard therapies. We show that azurin inhibits growth of cancer cells expressing caveolin-1, and this inhibition is only partially observed with mutant azurin. Finally, the simultaneous administration of azurin with anticancer therapeutic drugs (paclitaxel and doxorubicin) results in an enhancement in their activity, contrary to the mutated protein.

KW - Azurin

KW - caveolin-1

KW - lipid raft

KW - membrane order

KW - membrane-based anticancer therapy

UR - http://www.scopus.com/inward/record.url?scp=85052145540&partnerID=8YFLogxK

U2 - 10.1080/15384101.2018.1489178

DO - 10.1080/15384101.2018.1489178

M3 - Article

VL - 17

SP - 1649

EP - 1666

JO - Cell Cycle

JF - Cell Cycle

SN - 1538-4101

IS - 13

ER -